Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fish and Richardson
Deloitte
AstraZeneca
US Department of Justice
Covington
Chinese Patent Office
McKesson
Queensland Health

Generated: July 22, 2018

DrugPatentWatch Database Preview

Sebela Ireland Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for SEBELA IRELAND LTD, and what generic alternatives to SEBELA IRELAND LTD drugs are available?

SEBELA IRELAND LTD has seventeen approved drugs.

There are seven US patents protecting SEBELA IRELAND LTD drugs.

There are seventy-two patent family members on SEBELA IRELAND LTD drugs in thirty-two countries and two supplementary protection certificates in two countries.

Summary for Sebela Ireland Ltd
International Patents:72
US Patents:7
Tradenames:12
Ingredients:10
NDAs:17

Drugs and US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 RX Yes No 7,598,271 ➤ Try a Free Trial Y ➤ Try a Free Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 RX Yes Yes 7,598,271 ➤ Try a Free Trial Y ➤ Try a Free Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 RX Yes No 7,598,271 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990 4,828,251 ➤ Try a Free Trial
Sebela Ireland Ltd RIDAURA auranofin CAPSULE;ORAL 018689-001 May 24, 1985 3,635,945 ➤ Try a Free Trial
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 8,591,948 ➤ Try a Free Trial
Sebela Ireland Ltd RIDAURA auranofin CAPSULE;ORAL 018689-001 May 24, 1985 3,708,579 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SEBELA IRELAND LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-12-02
➤ Subscribe Capsules 7.5 mg ➤ Subscribe 2014-04-07

Non-Orange Book US Patents for Sebela Ireland Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,433,680 Topical compositions and methods for making and using same ➤ Try a Free Trial
9,446,131 Topical compositions and methods for making and using same ➤ Try a Free Trial
5,874,447 4-Phenylpiperidine compounds for treating depression ➤ Try a Free Trial
9,452,173 Topical compositions and methods for making and using same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Sebela Ireland Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0038 France ➤ Try a Free Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
Medtronic
Chinese Patent Office
Johnson and Johnson
McKinsey
Mallinckrodt
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.